Literature DB >> 9691143

Cytokines and soluble adhesion molecules in sickle cell anemia patients during hydroxyurea therapy.

A W Saleh1, A J Duits, A Gerbers, C de Vries, H F Hillen.   

Abstract

Hydroxyurea (HU) induces HbF production and can reduce painful crises in some patients with sickle cell anemia (SS). However, HbF induction alone cannot explain the beneficial effect of HU treatment as some patients experience clinical improvement while showing only minor increases in HbF. Other actions of HU, in particular its effects on vascular endothelium, adhesion molecule expression and cytokine production may also play a role in the final therapeutic outcome. In order to analyze these effects we studied the levels of interleukin-3 (IL-3), interleukin-6, granulocyte-macrophage colony-stimulating factor, erythropoietin, stem cell factor, soluble vascular adhesion molecule-1, soluble intercellular adhesion molecule-1, soluble E-selectin and soluble P-selectin in 7 SS patients before and during 5 months of HU treatment. Use of HU seems to have no detectable effect on soluble adhesion molecules, but the steady state levels of soluble vascular adhesion molecule-1 are enhanced in SS patients compared to normal controls. Of the cytokines studied, only IL-3 showed an increase during therapy, suggesting HU may induce early erythroid progenitors capable of producing HbF by a direct or indirect effect on IL-3 production. Remarkably, the steady state stem cell factor levels in sickle cell patients seemed to be decreased compared to healthy controls.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9691143     DOI: 10.1159/000040859

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  12 in total

1.  Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.

Authors:  Gregory J Kato; Sabrina Martyr; William C Blackwelder; James S Nichols; Wynona A Coles; Lori A Hunter; Marie-Luise Brennan; Stanley L Hazen; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

2.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Authors:  Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

3.  Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia.

Authors:  Rhiannon R Penkert; Julia L Hurwitz; Paul Thomas; Jason Rosch; Jola Dowdy; Yilun Sun; Li Tang; Jane S Hankins
Journal:  Haematologica       Date:  2017-11-16       Impact factor: 9.941

4.  Neutrophils and leucocyte adhesion molecules in sickle cell retinopathy.

Authors:  M Kunz Mathews; D S McLeod; C Merges; J Cao; G A Lutty
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

5.  Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease.

Authors:  Jing Li; Si-Yeon Jeong; Bei Xiong; Alan Tseng; Andrew B Mahon; Steven Isaacman; Victor R Gordeuk; Jaehyung Cho
Journal:  Haematologica       Date:  2019-10-31       Impact factor: 9.941

6.  Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.

Authors:  Jeffrey D Lebensburger; Thad Howard; Yunming Hu; Tamara I Pestina; Geli Gao; Melissa Johnson; Stanislav S Zakharenko; Russell E Ware; Elaine I Tuomanen; Derek A Persons; Jason W Rosch
Journal:  Blood       Date:  2011-11-30       Impact factor: 22.113

Review 7.  Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.

Authors:  Gregory J Kato; Mark T Gladwin
Journal:  JAMA       Date:  2008-12-10       Impact factor: 56.272

Review 8.  Sickle red cell-endothelium interactions.

Authors:  Dhananjay K Kaul; Eileen Finnegan; Gilda A Barabino
Journal:  Microcirculation       Date:  2009-01       Impact factor: 2.628

9.  Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease.

Authors:  Maria L Jison; Peter J Munson; Jennifer J Barb; Anthony F Suffredini; Shefali Talwar; Carolea Logun; Nalini Raghavachari; John H Beigel; James H Shelhamer; Robert L Danner; Mark T Gladwin
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

10.  Comparative Analysis of Pain Behaviours in Humanized Mouse Models of Sickle Cell Anemia.

Authors:  Jianxun Lei; Barbara Benson; Huy Tran; Solomon F Ofori-Acquah; Kalpna Gupta
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.